Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

Clin Microbiol Infect. 2016 Jan;22(1):98.e7-98.e10. doi: 10.1016/j.cmi.2015.09.028. Epub 2015 Oct 8.

Abstract

Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT.

Keywords: Human immunodeficiency virus 1 infection; human immunodeficiency virus 1 treatment; male genital tract; protease inhibitor monotherapy; triple therapy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV Protease Inhibitors / therapeutic use*
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Middle Aged
  • Semen / virology*
  • Treatment Outcome
  • Virus Shedding / drug effects*

Substances

  • HIV Protease Inhibitors